- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03925532
Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant
A Phase II Multicenter, Single Arm, Open-Label Trial to Evaluate the Efficacy and Safety of Denosumab in Treatment of Post-Allogenic Hematopoietic Stem Cell Transplant Bone Loss
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the efficacy and safety of denosumab therapy for the treatment of bone loss in patients who have received an allogeneic hematopoietic stem cell transplant.
OUTLINE:
Patients receive 2 doses of denosumab subcutaneously (SC) between days 70-130 and days 250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease progression or unacceptable toxicity.
After completion of study treatment patients are followed up at 6 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient has undergone an Allogeneic Hematopoietic Stem Cell Transplant
- The patient has completed a base line dual x-ray absorptiometry (DXA) scan =< 6 months prior to transplantation
- The patient has completed a post-transplant DXA scan at day 100 (+/- 30 days) or up to 6 months post transplantation
- The patient has completed and passed a dental clearance exam up to 6 months prior to transplant or 6 months after transplant
- Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria:
- The patient has a history of a hypersensitivity reaction to denosumab
- The patient has a history of osteonecrosis of the jaw
The patient has predisposing risk factors for hypocalcemia including the following:
- Hypoparathyroidism
- Creatinine clearance (CrCl) < 30 mL/min
- Dialysis
- Malabsorption syndrome
- The patient has history of any bone fracture =< 30 days prior to denosumab therapy
- Pregnant or nursing female patients.
- The patient has clinically significant GVHD leading to hospitalization at the time of denosumab dose per prescriber discretion.
- The patient has clinically significant infection leading to hospitalization at the time of denosumab dose (excluding hospitalization due to complexity of treatment leading to inability to treat outpatient, ie. Foscarnet) per prescriber discretion
- The patient is unwilling or unable to follow protocol requirements
- The patient has any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug including relapsed malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Supportive Care (denosumab)
Patients receive 2 doses of denosumab SC between days 70-130 and days 250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease progression or unacceptable toxicity.
|
Given SC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Total Hip Percent Change in Bone Mineral Density (BMD)
Time Frame: At baseline and 465 days post-HSCT
|
Day 0 dual x-ray absorptiometry (DXA) scan and day 465 DXA scan will be compared based on the percent change in BMD in the Total hip in allogeneic HSCT patients who have experienced either at least 5% BMD loss between baseline (pre- HSCT) and day + 100 post-HSCT, or who have osteopenia or osteoporosis at either the pre-bone marrow transplant or day + 100 DXA scan.
|
At baseline and 465 days post-HSCT
|
Slope in Hip Bone Mineral Density (g/cm^2 Per Day) Regressed on Time in Dual
Time Frame: From the time of enrollment up to 465 days post-HSCT
|
Parameter estimate of the slope of the regression model of the hip bone mineral density change at day 465 post-HSCT regressed on the enrollment BMD levels.
|
From the time of enrollment up to 465 days post-HSCT
|
Mean Lumbar Spine Percent Change in Bone Mineral Density (BMD)
Time Frame: At baseline and 465 days post-HSCT
|
Day 0 dual x-ray absorptiometry (DXA) scan and day 465 DXA scan will be compared based on the percent change in BMD in lumbar spine in allogeneic HSCT patients who have experienced either at least 5% BMD loss between baseline (pre- HSCT) and day + 100 post-HSCT, or who have osteopenia or osteoporosis at either the pre-bone marrow transplant or day + 100 DXA scan.
|
At baseline and 465 days post-HSCT
|
Mean Total Hip Percent Change in Bone Mineral Density (BMD)
Time Frame: At baseline, at time of enrollment (day 100 post-hematopoietic stem cell transplantation [HSCT])
|
Day 100 dual x-ray absorptiometry (DXA) scan will be compared based on the percent change in BMD in the Total hip in allogeneic HSCT patients who have experienced either at least 5% BMD loss between baseline (pre- HSCT) and day + 100 post-HSCT, or who have osteopenia or osteoporosis at either the pre-bone marrow transplant or day + 100 DXA scan.
|
At baseline, at time of enrollment (day 100 post-hematopoietic stem cell transplantation [HSCT])
|
Slope in Lumbar Spine Bone Mineral Density (g/cm^2 Per Day) Regressed on Time in Dual
Time Frame: From the time of enrollment up to 465 days post-HSCT
|
Parameter estimate of the slope of the regression model of the lumbar spine bone mineral density change at day 465 post-HSCT regressed on the enrollment BMD levels.
|
From the time of enrollment up to 465 days post-HSCT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Lumbar Spine Percent Change in BMD
Time Frame: Baseline up to 100 days post-HSCT
|
Day 100 dual x-ray absorptiometry (DXA) scan will be compared based on the percent change in BMD in the lumbar spine in allogeneic HSCT patients who have experienced either at least 5% BMD loss between baseline (pre- HSCT) and day + 100 post-HSCT, or who have osteopenia or osteoporosis at either the pre-bone marrow transplant or day + 100 DXA scan.
|
Baseline up to 100 days post-HSCT
|
Frequency of Bone Fractures
Time Frame: Up to 1 year post-HSCT
|
The number of participants with bone fractures tabulated overall
|
Up to 1 year post-HSCT
|
Number of Participants That Experienced Any AE
Time Frame: Up to 30 days
|
Including but not limited to the following: Injection/hypersensitivity related reactions; osteonecrosis of the jaw; graft versus host disease.
Will be assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5 and tabulated by grade.
|
Up to 30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Philip L McCarthy, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I 78618 (Other Identifier: Roswell Park Cancer Institute)
- NCI-2019-01921 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on Denosumab
-
AmgenCompletedOsteoporosis | Osteopenia | Low Bone Mineral Density | Low Bone Mass | Males With Osteoporosis
-
GlaxoSmithKlineCompletedOsteoporosis, PostmenopausalKorea, Republic of
-
Samsung Bioepis Co., Ltd.CompletedPostmenopausal OsteoporosisPoland
-
AmgenCompletedPostmenopausal OsteoporosisUnited States, Denmark, Poland, Canada
-
AmgenCompletedHealthy VolunteerUnited States
-
Borstkanker Onderzoek GroepAmgenWithdrawn
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingMetastatic Breast Cancer | Bone Metastases | Metastatic Prostate CancerSwitzerland, Germany, Austria
-
Luye Pharma Group Ltd.ParexelCompleted
-
National Cancer Institute (NCI)TerminatedOvarian CarcinomaUnited States, Israel